Who makes Technetium Tc 99M Arcitumomab?

Technetium Tc 99M Arcitumomab is developed by Immunomedics.

What development phase is Technetium Tc 99M Arcitumomab in?

Technetium Tc 99M Arcitumomab is FDA-approved (marketed).

What is the generic name of Technetium Tc 99M Arcitumomab?

ARCITUMOMAB is the generic (nonproprietary) name of Technetium Tc 99M Arcitumomab.

Last reviewed 2026-04-20 · How we verify

Technetium Tc 99M Arcitumomab (ARCITUMOMAB)

Immunomedics · FDA-approved approved Monoclonal antibody Quality 10/100

At a glance

Generic name	ARCITUMOMAB
Sponsor	Immunomedics
Modality	Monoclonal antibody
Therapeutic area	Oncology
Phase	FDA-approved
First approval	1996

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Technetium Tc 99M Arcitumomab CI brief — competitive landscape report
Technetium Tc 99M Arcitumomab updates RSS · CI watch RSS
Immunomedics portfolio CI